durvalumab (Imfinzi®)

Status: Excluded due to NICE appraisal
Product meets AWMSG exclusion criteria due to NICE appraisal ID6317: Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]
Medicine details
Medicine name	durvalumab (Imfinzi®)
Formulation	50 mg/mL concentrate for solution for infusion
Reference number	5372
Indication	In combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with: • IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) • IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).
Company	AstraZeneca UK Ltd
BNF chapter	Malignant disease & immunosuppression
Assessment type	N/A
Status	Excluded due to NICE appraisal
NICE guidance	ID6317: Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]